Compare ASTRAZENECA PHARMA with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PIRAMAL ENTERPRISES ASTRAZENECA PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 89.3 8.8 1,011.5% View Chart
P/BV x 27.1 0.6 4,460.1% View Chart
Dividend Yield % 0.0 2.9 -  

Financials

 ASTRAZENECA PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
PIRAMAL ENTERPRISES
Mar-19
ASTRAZENECA PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,2783,303 38.7%   
Low Rs8831,797 49.1%   
Sales per share (Unadj.) Rs228.4716.5 31.9%  
Earnings per share (Unadj.) Rs10.479.7 13.0%  
Cash flow per share (Unadj.) Rs16.3107.9 15.1%  
Dividends per share (Unadj.) Rs028.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs98.81,477.5 6.7%  
Shares outstanding (eoy) m25.00184.45 13.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.73.6 132.9%   
Avg P/E ratio x104.232.0 325.8%  
P/CF ratio (eoy) x66.423.6 281.2%  
Price / Book Value ratio x10.91.7 633.8%  
Dividend payout %035.1 0.0%   
Avg Mkt Cap Rs m27,008470,292 5.7%   
No. of employees `0001.47.8 17.3%   
Total wages/salary Rs m1,53522,504 6.8%   
Avg. sales/employee Rs Th4,210.916,899.4 24.9%   
Avg. wages/employee Rs Th1,132.22,877.7 39.3%   
Avg. net profit/employee Rs Th191.11,879.9 10.2%   
INCOME DATA
Net Sales Rs m5,710132,153 4.3%  
Other income Rs m1233,128 3.9%   
Total revenues Rs m5,833135,281 4.3%   
Gross profit Rs m46366,290 0.7%  
Depreciation Rs m1475,202 2.8%   
Interest Rs m044,097 0.0%   
Profit before tax Rs m43820,119 2.2%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1798,611 2.1%   
Profit after tax Rs m25914,701 1.8%  
Gross profit margin %8.150.2 16.2%  
Effective tax rate %40.842.8 95.4%   
Net profit margin %4.511.1 40.8%  
BALANCE SHEET DATA
Current assets Rs m3,209122,742 2.6%   
Current liabilities Rs m2,070310,810 0.7%   
Net working cap to sales %20.0-142.3 -14.0%  
Current ratio x1.60.4 392.7%  
Inventory Days Days7223 313.6%  
Debtors Days Days3539 89.9%  
Net fixed assets Rs m790116,904 0.7%   
Share capital Rs m50369 13.6%   
"Free" reserves Rs m2,419272,161 0.9%   
Net worth Rs m2,469272,530 0.9%   
Long term debt Rs m0270,196 0.0%   
Total assets Rs m4,605856,261 0.5%  
Interest coverage xNM1.5-  
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.20.2 803.3%   
Return on assets %5.66.9 81.9%  
Return on equity %10.55.4 194.5%  
Return on capital %17.712.4 142.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30015,200 2.0%   
Fx outflow Rs m2,0154,889 41.2%   
Net fx Rs m-1,71510,312 -16.6%   
CASH FLOW
From Operations Rs m88-115,975 -0.1%  
From Investments Rs m-94-8,265 1.1%  
From Financial Activity Rs mNA107,525 0.0%  
Net Cashflow Rs m-6-16,650 0.0%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.0 7.5%  
FIIs % 15.7 26.6 59.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 16.5 55.2%  
Shareholders   12,856 93,274 13.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

SUN PHARMA Surges by 6%; BSE HEALTHCARE Index Up 4.7% (Market Updates)

Apr 9, 2020 | Updated on Apr 9, 2020

SUN PHARMA share price has surged by 6% and its current market price is Rs 470. The BSE HEALTHCARE is up by 4.7%. The top gainers in the BSE HEALTHCARE Index are SUN PHARMA (up 6.3%) and ASTRAZENECA PHARMA (up 5.2%). The top losers are IPCA LABS (down 0.8%) and TORRENT PHARMA (down 0.9%).

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound(Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 9, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - DR. REDDYS LAB COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS